ribociclib,palbociclib
novartis,pfizer
['maintain trial', 'bcsm', 'mbc', 'ribociclib']
maintain trial
switch et &amp; continue cdk4/6 inhibitor (ribociclib) at 1st prog in #mbc improved mpfs mpfs of 5.29 (ribo + et) vs 2.76 with et alone 87% prior palbo,14% prior ribo, 2% prior abema 42% has esr1 mutation at study entry in pts w ctdna. #asco22 #bcsm
Breast Medical Oncologist @RutgersCancer @Rutgers and @RWJMS wife/mom/baker/world traveler #bcsm